Abstract：ObjectiveTo study the effect of nifekaran combined with propafenone on heart rate variability (HRV) and inflammatory response in elderly patients with arrhythmia. MethodsEighty elderly patients with arrhythmia were selected as study objects. They were divided into control group and combination group according to treatment plan, each with 40 cases. The control group was treated with propafenone while the combination group was treated with nifekaran injection plus propafenone. We compared the clinical efficacy between the two groups. HRV indexes (SDNN, SDANN, rMSSD and PNN50), levels of hemorheological indexes ［fibrinogen (Fib), low shear rate blood viscosity (LBV), plasma viscosity (PV) and high shear rate blood viscosity (HBV)］, and serum inflammatory related factors ［hypersensitive Creactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), nuclear factor κB (NF-κB), polyadenylate diphosphoribose polymerase 1 (PARP1)］ before and after treatment as well as incidence of adverse reactions were also made comparison between the two groups. ResultsThe total clinical effective rate of the combination group was higher than that of the control group (95.00% vs. 77.50%, P＜0.05). After 14 days of treatment, the values of SDNN, SDANN, rMSSD and PNN50 in the combination group were significantly higher than those in the control group (P<0.05), while the levels of Fib, LBV, PV and HBV in the combination group were significantly lower than those in the control group (P<0.05). Compared with the control group, the levels of serum PARP1, TNF-α, hs-CRP and NF-κB in the combination group were lower after 14 days of treatment (P<0.05). The total incidence of adverse reactions between the two groups showed no statistically significant difference (P>0.05). ConclusionNifekaran combined with propafenone could improve HRV and hemorheology, relieve inflammation state, and improve efficacy with high safety in elderly patients with arrhythmia.
